Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Peptide deformylase (PDF) activity was traditionally associated with prokaryotic ribosomal protein synthesis.
• This process involves initiating new peptides with N-formylated methionine.
• Its necessity in mammalian cells, particularly in mitochondria, was previously unestablished.

Purpose of the Study:

• To identify and characterize a novel human peptide deformylase (HsPDF).
• To investigate the role of HsPDF in mitochondrial protein synthesis.
• To evaluate the therapeutic potential of inhibiting HsPDF in cancer treatment.

Main Methods:

• Identification and localization of human peptide deformylase (HsPDF) to mitochondria.
• Synthesis and testing of actinonin analogs for HsPDF inhibition and antiproliferative activity.
• Validation using small interfering RNA (siRNA) to inhibit HsPDF expression.
• Assessment of mitochondrial function (membrane potential, ATP levels) and in vivo tumor growth inhibition.

Main Results:

• A novel human mitochondrial peptide deformylase (HsPDF) was identified.
• Actinonin and its analogs potently inhibited HsPDF and human cancer cell proliferation.
• HsPDF inhibition led to mitochondrial dysfunction and ATP depletion in tumor cells.
• Actinonin demonstrated efficacy in inhibiting human prostate and lung cancer growth in animal models.

Conclusions:

• HsPDF is a functional human mitochondrial enzyme.
• HsPDF represents a novel and selective target for anticancer drug development.
• Actinonin-based antibiotics show potential as a new therapeutic strategy against various cancers.